Cargando…

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schirrmacher, Volker, van Gool, Stefaan, Stuecker, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783952/ https://www.ncbi.nlm.nih.gov/pubmed/31480379 http://dx.doi.org/10.3390/biomedicines7030066

Ejemplares similares

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies
por: Schirrmacher, Volker, et al.
Publicado: (2014)

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
por: Fournier, Philippe, et al.
Publicado: (2013)

Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
por: Schirrmacher, Volker
Publicado: (2022)

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
por: Schirrmacher, Volker, et al.
Publicado: (2020)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
por: Van Gool, Stefaan W., et al.
Publicado: (2022)

Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer
por: Schirrmacher, Volker, et al.
Publicado: (2008)

Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
por: Van Gool, Stefaan W., et al.
Publicado: (2020)

Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!
por: Schirrmacher, Volker
Publicado: (2016)

Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
por: Huang, Fang, et al.
Publicado: (2022)

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
por: Van Gool, Stefaan W., et al.
Publicado: (2020)

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
por: Schirrmacher, Volker
Publicado: (2020)

Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
por: Schirrmacher, Volker
Publicado: (2017)

Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
por: Chai, Zheng, et al.
Publicado: (2014)

Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
por: Schirrmacher, Volker, et al.
Publicado: (2014)

Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma
por: de Graaf, J. Fréderique, et al.
Publicado: (2022)

Therapeutic potential of oncolytic Newcastle disease virus: a critical review
por: Tayeb, Shay, et al.
Publicado: (2015)

The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus
por: Pathak, Upasana, et al.
Publicado: (2023)

Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
por: Buijs, Pascal, et al.
Publicado: (2015)

Adaptation of the Newcastle Disease Virus to Cell Cultures for Enhancing Its Oncolytic Properties
por: Yurchenko, K. S., et al.
Publicado: (2019)

Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses
por: Liu, Tianyan, et al.
Publicado: (2020)

ATM-mediated DNA double-strand break response facilitated oncolytic Newcastle disease virus replication and promoted syncytium formation in tumor cells
por: Ren, Shanhui, et al.
Publicado: (2020)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma
por: Baiocchi, Leonardo, et al.
Publicado: (2022)

Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis
por: Keshavarz, Mohsen, et al.
Publicado: (2020)

Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma
por: Numpadit, Supaporn, et al.
Publicado: (2023)

Papaverine Enhances the Oncolytic Effects of Newcastle Disease Virus on Breast Cancer In Vitro and In Vivo
por: Akram, Sura, et al.
Publicado: (2023)

Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases
por: Vorobyev, P. O., et al.
Publicado: (2022)

Update on oncolytic viral therapy – targeting angiogenesis
por: Tysome, James R, et al.
Publicado: (2013)

Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
por: Jiang, Ke, et al.
Publicado: (2018)

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity
por: Harper, James, et al.
Publicado: (2021)

Oncolytic viruses in cancer therapy
por: Vähä-Koskela, Markus J.V., et al.
Publicado: (2007)

Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

The Application of Evidence-Based Medicine in Individualized Medicine
por: Van de Vliet, Peter, et al.
Publicado: (2023)

Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells
por: Meng, Gang, et al.
Publicado: (2014)

Anti-Tumor Effects of an Oncolytic Adenovirus Expressing Hemagglutinin-Neuraminidase of Newcastle Disease Virus in Vitro and in Vivo
por: He, Dongyun, et al.
Publicado: (2014)

STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
por: Shao, Xiaoyan, et al.
Publicado: (2019)

Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma
por: Vijayakumar, Gayathri, et al.
Publicado: (2019)

Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
por: Burke, Shannon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j57oeu2taia1j03a6anio4iufq